What is your recommendation for medication management in a 57-year-old man with recent ischemic strokes who is taking Cardura (doxazosin) 8 mg daily, Beloc (metoprolol) 25 mg daily, and Eliquis (apixaban) 5 mg twice daily?

Medication Recommendation for Post-Stroke Anticoagulation Management

Continue Eliquis (apixaban) 5 mg twice daily as prescribed, optimize blood pressure control by increasing Beloc to at least 50 mg daily (target higher if tolerated), and discontinue Cardura immediately as alpha-blockers increase stroke risk and orthostatic hypotension in this population.

Anticoagulation Strategy

The current Eliquis regimen is appropriate and should be maintained. For patients who experience ischemic stroke while on a DOAC, continuing the same DOAC is superior to switching to warfarin or another DOAC 1. The evidence shows that patients remaining on their initial DOAC have significantly lower risks of recurrent ischemic stroke (RR 0.55), intracranial hemorrhage (RR 0.37), and hemorrhagic events (RR 0.44) compared to those switched to warfarin 1.

Recent data specifically supports apixaban's efficacy in secondary stroke prevention. In patients with recent ischemic stroke, apixaban demonstrates lower mortality rates compared to warfarin, with particularly strong evidence in those with left ventricular dysfunction 2. The 2024 analysis showed that even when strokes occur during DOAC therapy, apixaban-treated patients have better prognoses than warfarin-treated patients 3.

The current 5 mg twice daily dose is correct based on FDA labeling 4. Dose reduction to 2.5 mg twice daily is only indicated if the patient has at least TWO of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. At age 57, this patient does not meet reduction criteria unless both weight and renal function criteria are present.

Blood Pressure Optimization - Critical Priority

Hypertension management is the single most important modifiable risk factor for secondary stroke prevention 5. The current Beloc (metoprolol) dose of 25 mg daily is subtherapeutic for stroke prevention.

• Increase metoprolol to 50-100 mg daily minimum, titrating to achieve blood pressure <130/80 mmHg
• Beta-blockers are appropriate for post-stroke patients, particularly if there is concurrent atrial fibrillation or coronary disease
• Intensive blood pressure control reduces recurrent stroke risk more effectively than standard control 5

Discontinue Cardura (Doxazosin)

Alpha-blockers like doxazosin are NOT recommended for stroke prevention and may increase harm through:

• Orthostatic hypotension - dramatically increases fall risk and potential for traumatic intracranial hemorrhage in anticoagulated patients
• No stroke prevention benefit - alpha-blockers do not reduce stroke risk compared to other antihypertensive classes
• Inferior cardiovascular outcomes - the ALLHAT trial demonstrated alpha-blockers have worse cardiovascular outcomes than other agents

If doxazosin was prescribed for benign prostatic hyperplasia rather than hypertension, consider switching to tamsulosin (more uroselective, less hypotension) or 5-alpha reductase inhibitors.

Additional Secondary Prevention Measures

Per 2021 AHA/ASA guidelines 5:

• Add high-intensity statin therapy if not already prescribed (atorvastatin 40-80 mg or rosuvastatin 20-40 mg)
• Initiate low-salt Mediterranean diet - specific dietary pattern shown to reduce recurrent stroke
• Screen for diabetes and optimize glycemic control if present
• Smoking cessation if applicable - absolute requirement
• Supervised physical activity program - stroke patients are at high risk for sedentary behavior

Critical Monitoring Parameters

• Blood pressure: Target <130/80 mmHg, check orthostatic vitals after any medication changes
• Renal function: Monitor creatinine every 6-12 months (apixaban is 27% renally excreted)
• Bleeding signs: Educate on signs of major bleeding given anticoagulation
• Medication adherence: Apixaban requires strict twice-daily dosing - missing doses increases stroke risk

Common Pitfalls to Avoid

1. Do not switch anticoagulants without compelling indication - the evidence strongly favors continuing the current DOAC 1
2. Do not undertitrate blood pressure medications - intensive control is essential 5
3. Do not continue alpha-blockers in anticoagulated stroke patients - fall risk is prohibitive
4. Do not add antiplatelet therapy to anticoagulation - combination therapy increases bleeding without stroke benefit except in very specific scenarios (severe intracranial stenosis) 5

5, 4, 3, 2, 1